Oramed Pharmaceuticals Inc. (ORMP)

Compare

2.1300

-0.0100

(-0.47%)

At close: April 1 at 4:00:01 PM EDT

2.1300

0.00

(0.00%)

After hours: April 1 at 4:05:07 PM EDT

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential

As the United States stock market grapples with volatility, driven by concerns about economic health and shifting investor sentiment, opportunities in lesser-known areas like penny stocks are gaining attention. While the term 'penny stocks' might seem outdated, these investments often represent smaller or newer companies that can offer growth potential at lower price points. When backed by strong financials and sound fundamentals, they provide investors a chance to uncover hidden value amidst...

Simply Wall St. 19 days ago

TLSA

ORMP
-0.47%
AVIR
Oramed Pharmaceuticals Issues Letter to Shareholders

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a letter to its shareholders from its President and Chief Executive Officer Nadav Kidron.

PR Newswire 28 days ago

ORMP
-0.47%
Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch

As Wall Street navigates the complexities of tariffs and Federal Reserve Chair Jerome Powell's testimony, the U.S. stock market remains a mixed bag with indices showing varied performance. Amid these broader economic discussions, penny stocks continue to capture investor interest by offering potential growth opportunities at lower price points. While often associated with smaller or newer companies, these stocks can present compelling prospects when backed by strong financials and solid...

Simply Wall St. last month

ORMP
-0.47%
HOWL

VSTA
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that it has entered into definitive agreements to spin off its Protein Oral Delivery (POD™) technology into a newly formed joint venture, OraTech Pharmaceuticals Inc. ("OraTech"), with Hefei Tianhui Biotech Co., Ltd. ("HTIT"). This transaction is designed to accelerate the development and commercialization of Orame

PR Newswire last month

ORMP
-0.47%
3 US Penny Stocks With Market Caps Above $40M

As major U.S. stock indices reach new highs, buoyed by robust tech earnings and positive economic signals from the Federal Reserve, investors are exploring diverse opportunities across the market spectrum. Penny stocks, though often overlooked and considered a relic of past market trends, continue to attract attention due to their potential for growth within smaller or newer companies. By examining those with solid financial foundations, investors can uncover promising opportunities that...

Simply Wall St. 3 months ago

ORMP
-0.47%
HGBL
ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent Agreements

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Planning Phase 3 Oral Insulin study under revised protocol, new CRO agreement in place Oramed Pharmaceuticals (NASDAQ:ORMP) has pivoted its clinical R&D focus to prioritize studying ORMD 0801 for subpopulations of patients with pooled specific parameters who responded well to oral insulin in its prior trial. The subpopulation included

Zacks Small Cap Research 3 months ago

ORMP
-0.47%
US Penny Stocks To Watch: 3 Picks With Market Caps Over $40M

As the U.S. stock market experiences a rally led by the technology sector, investors are closely monitoring developments such as the presidential election and upcoming Federal Reserve decisions on interest rates. In this context, penny stocks continue to capture attention for their potential to offer both affordability and growth opportunities, despite being considered a somewhat outdated term. These smaller or newer companies can provide unique investment prospects when they demonstrate...

Simply Wall St. 4 months ago

ORMP
-0.47%
CMPX

INDO
Scilex Holding Starts $50 Million Registered Direct Offering of Convertible Notes

Scilex Holding Starts $50 Million Registered Direct Offering of Convertible Notes

PREMIUM
MT Newswires 5 months ago

SCLXW

ORMP
-0.47%
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the execution of definitive agreements for the restructuring of a portion of its existing Senior Secured Promissory Note from Scilex Holding Company (Nasdaq: SCLX) ("Scilex"), a company focused on non-opioid pain management products.

PR Newswire 5 months ago

ORMP
-0.47%
ORMP: Balance Sheet Strong, Potential Benefits of Investments, JVs, Buybacks

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Solid cash & equivalents position as former CFO resumes role… Oramed Pharmaceuticals (NASDAQ:ORMP) has named its former Chief Financial Officer to the CFO position again. In June 2024, the company named Avraham Gabay as CFO, Secretary and Treasurer to replace former CFO David Silberman. Mr. Silberman had announced his intention to

Zacks Small Cap Research 6 months ago

ORMP
-0.47%
Oramed: Q2 Earnings Snapshot

NEW YORK (AP) — Oramed Pharmaceuticals Inc. ORMP) on Wednesday reported earnings of $9.2 million in its second quarter. The New York-based company said it had profit of 22 cents per share.

Associated Press Finance 7 months ago

ORMP
-0.47%
3 Micro-Cap Moonshots for Fearless Investors

When discussing micro-cap stocks, it’s important to recognize their general overlap with the world of penny stocks. These stocks trade as shares of companies with market capitalizations between $50 million and $300 million. While those numbers may sound worthy to the individual investor, they represent a generally risky position for a handful of reasons. The first is that micro-cap stocks are often derived from young and relatively unproven companies. Just because a company publicly trades on th

InvestorPlace 8 months ago

SPRO

ORMP
-0.47%
AMPY
Oramed Letter to Shareholders

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.

PR Newswire 9 months ago

ORMP
-0.47%
Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (the "Company") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced today that its Board of Directors has authorized a common stock repurchase plan allowing for the buy-back of up to $20,000,000 in maximum value of its common stock through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities

PR Newswire 9 months ago

ORMP
-0.47%
ORMP: Moving Oral Delivery Platform Forward, + Potential to Generate Royalties

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Leveraging protein oral delivery platform… Earlier this month, Oramed Pharmaceuticals (NASDAQ:ORMP) CFO David Silberman announced his intention to resign from the company effective July 12, 2024, citing personal reasons. Oramed has launched a search for a new CFO and notes that it believes it has the financial flexibility and balance

Zacks Small Cap Research 9 months ago

ORMP
-0.47%
GNMLF
Oramed Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)

Oramed Pharmaceuticals ( NASDAQ:ORMP ) First Quarter 2024 Results Key Financial Results Net income: US$1.54m (up from...

Simply Wall St. 10 months ago

ORMP
-0.47%

Performance Overview

Return	ORMP	S&P 500 (^GSPC)
YTD	-11.98%	-4.23%
1-Year	-24.73%	+7.42%
3-Year	-75.38%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Oramed Pharmaceuticals Inc. (ORMP)

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential

Oramed Pharmaceuticals Issues Letter to Shareholders

Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin

3 US Penny Stocks With Market Caps Above $40M

ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent Agreements

US Penny Stocks To Watch: 3 Picks With Market Caps Over $40M

Scilex Holding Starts $50 Million Registered Direct Offering of Convertible Notes

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

ORMP: Balance Sheet Strong, Potential Benefits of Investments, JVs, Buybacks

Oramed: Q2 Earnings Snapshot

3 Micro-Cap Moonshots for Fearless Investors

Oramed Letter to Shareholders

Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock

ORMP: Moving Oral Delivery Platform Forward, + Potential to Generate Royalties

Oramed Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)

Performance Overview